Ivacaftor deuterated

Drug Profile

Ivacaftor deuterated

Alternative Names: C-10355; C-10358; CTP-656; D-ivacaftor; Deuterated ivacaftor

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Concert Pharmaceuticals
  • Class Amides; Aminophenols; Organic deuterium compounds; Quinolones; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 01 Dec 2016 Phase-II clinical trials in Cystic fibrosis in USA (PO) (NCT02971839)
  • 27 Oct 2016 Pharmacokinetics data from a phase I trial in in Healthy volunteers released by Concert Pharmaceuticals
  • 10 Jun 2016 Adverse events and updated pharmacokinetics data from a phase I trial in Cystic fibrosis (In Volunteers) released by Concert Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top